Ketamine Versus Magnesium Sulphate as Adjuvants for ESPB in Breast Cancer Surgery

Model scores of the 29,894 trials active now.

Model score 7% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-04-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: breast cancerorganiiillnessmodified
  Phrases that lowered it: efficacy andand safetysafety ofaimto compare
• Sponsor's past termination rate: 0.3% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: not given (lowers risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Number of arms: 3 (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 14.3% (lowers risk) · Drug's FDA history
• Responsible party: principal investigator (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Design: parallel (raises risk) · Design
• Drug's FAERS reports marked serious: 93.5% (raises risk) · Drug's FDA history
• Maximum age: 60 (lowers risk) · Who can join
• Sponsor's past trials: 308 (lowers risk) · Sponsor's track record
• Blinding: double (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 303 (raises risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Comparing the Perioperative Analgesic Effect of Two Different Volumes of Local Anesthetic Solution in Erector Spinae Plane Block in Patients Undergoing Modified Radical Mastectomy NCT05813158 · started 2022 · scored riskier than 4% of active trials completed
• Dexmedetomedine and Ketamine in Erector Spinae Block for Postoperative Analgesia Following Mastectomy. NCT05727098 · started 2023 · scored riskier than 16% of active trials completed
• Magnesium Sulphate Versus Ketamine as an Adjuvant to Bupivacaine in Pectoral Nerve Block During Mastectomy NCT05663801 · started 2022 · scored riskier than 10% of active trials completed
• Ketamine as Adjunctive Analgesic With Bupivacaine in Paravertebral Analgesia for Breast Cancer Surgery NCT02462681 · started 2015 · scored riskier than 8% of active trials completed
• RCT Comparing ESPB Solutions in Breast Surgery NCT04603911 · started 2020 · scored riskier than 81% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.